Company HCW Biologics Inc.

Equities

HCWB

US40423R1059

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 02:00:01 14/05/2024 am IST			5-day change	1st Jan Change
1.12 ^USD	-0.88%		-12.50%	-8.57%

01/04	HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01/04	HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-Î² and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.

Number of employees: 45

USD in Million	2022	Weight	2023	Weight	Delta
Novel Immunotherapies 100.0 %	7	100.0 %	3	100.0 %	-57.72%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	7	100.0 %	3	100.0 %	-57.72%

Managers	Title	Age	Since
Hing Wong FOU	Founder	70	02/18/02
Rebecca Byam DFI	Director of Finance/CFO	68	01/19/01
Peter Rhode CTO	Chief Tech/Sci/R&D Officer	66	01/19/01
Raquel Diaz HRO	Human Resources Officer	-	01/18/01
Nicole Valdivieso LAW	General Counsel	-	01/19/01
Jin-an Jiao PRN	Corporate Officer/Principal	65	01/19/01
Lee Flowers PRN	Corporate Officer/Principal	78	01/19/01

Members of the board	Title	Age	Since
Scott Garrett CHM	Chairman	73	01/21/01
Hing Wong FOU	Founder	70	02/18/02
Rick Greene BRD	Director/Board Member	59	01/21/01
Lisa Giles BRD	Director/Board Member	65	25/21/25
Gary Winer BRD	Director/Board Member	64	25/21/25

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,823,394	18,040,269 ( 47.70 %)	0	47.70 %

Name	Equities	%	Valuation
Hing Wong 42.45 %	16,054,156	42.45 %	23 M $
Axone Capital 5.036 %	1,904,762	5.036 %	3 M $
Rebecca Byam 3.654 %	1,381,909	3.654 %	2 M $
Scott Garrett 0.7082 %	267,858	0.7082 %	391 073 $
Lee Flowers 0.5030 %	190,238	0.5030 %	277 747 $
HighTower Advisors LLC 0.4754 %	179,810	0.4754 %	262 523 $
Avantax Planning Partners, Inc. 0.4753 %	179,777	0.4753 %	262 474 $
Cresset Asset Management LLC 0.3490 %	131,990	0.3490 %	192 705 $
Pullen Investment Management LLC 0.2250 %	85,116	0.2250 %	124 269 $
Bridgeway Capital Management LLC 0.2239 %	84,700	0.2239 %	123 662 $

HCW Biologics Inc.

2929 North Commerce Parkway

33025, Miramar

http://www.hcwbiologics.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.12 USD

Average target price

4 USD

Spread / Average Target

+257.14%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
HCW BIOLOGICS INC.	-8.57%	42.36M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	111B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	21.93B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-7.66%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-10.09%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.45B

Bio Therapeutic Drugs